GB0605735D0 - Composition and method for mediating an immune response - Google Patents

Composition and method for mediating an immune response

Info

Publication number
GB0605735D0
GB0605735D0 GBGB0605735.0A GB0605735A GB0605735D0 GB 0605735 D0 GB0605735 D0 GB 0605735D0 GB 0605735 A GB0605735 A GB 0605735A GB 0605735 D0 GB0605735 D0 GB 0605735D0
Authority
GB
United Kingdom
Prior art keywords
mediating
composition
immune response
immune
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0605735.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Priority to GBGB0605735.0A priority Critical patent/GB0605735D0/en
Publication of GB0605735D0 publication Critical patent/GB0605735D0/en
Priority to CN2013102732781A priority patent/CN103396495A/zh
Priority to EP07733568A priority patent/EP2007807A2/en
Priority to US12/225,454 priority patent/US20090186025A1/en
Priority to PCT/GB2007/050143 priority patent/WO2007107797A2/en
Priority to JP2009500939A priority patent/JP2009529906A/ja
Priority to CNA2007800185186A priority patent/CN101448854A/zh
Priority to US13/470,227 priority patent/US20120225067A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0605735.0A 2006-03-22 2006-03-22 Composition and method for mediating an immune response Ceased GB0605735D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0605735.0A GB0605735D0 (en) 2006-03-22 2006-03-22 Composition and method for mediating an immune response
CN2013102732781A CN103396495A (zh) 2006-03-22 2007-03-22 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白
EP07733568A EP2007807A2 (en) 2006-03-22 2007-03-22 Composition and method for mediating an immune response
US12/225,454 US20090186025A1 (en) 2006-03-22 2007-03-22 Fusion Protein Comprising an Fc Receptor Binding Polypeptide and an Antigenic Polypeptide for Mediating an Immune Response
PCT/GB2007/050143 WO2007107797A2 (en) 2006-03-22 2007-03-22 Fusion protein comprising an fc receptor binding polypeptide and an antigenic polypeptide for mediating an immune response
JP2009500939A JP2009529906A (ja) 2006-03-22 2007-03-22 免疫応答を調節するための組成物および方法
CNA2007800185186A CN101448854A (zh) 2006-03-22 2007-03-22 包含结合Fc受体的多肽和抗原性多肽的用于介导免疫应答的融合蛋白
US13/470,227 US20120225067A1 (en) 2006-03-22 2012-05-11 Composition and Method for Mediating an Immune Response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0605735.0A GB0605735D0 (en) 2006-03-22 2006-03-22 Composition and method for mediating an immune response

Publications (1)

Publication Number Publication Date
GB0605735D0 true GB0605735D0 (en) 2006-05-03

Family

ID=36383953

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0605735.0A Ceased GB0605735D0 (en) 2006-03-22 2006-03-22 Composition and method for mediating an immune response

Country Status (6)

Country Link
US (2) US20090186025A1 (enExample)
EP (1) EP2007807A2 (enExample)
JP (1) JP2009529906A (enExample)
CN (2) CN101448854A (enExample)
GB (1) GB0605735D0 (enExample)
WO (1) WO2007107797A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615266D0 (en) * 2006-08-01 2006-09-06 Immunobiology Ltd Composition and method for mediating an immune response
CA2915168C (en) 2007-01-30 2017-05-23 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
TWI423985B (zh) * 2007-02-23 2014-01-21 Baylor Res Inst 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用
WO2011044158A1 (en) 2009-10-09 2011-04-14 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
AU2013295647B2 (en) * 2012-07-26 2018-02-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
EP3253797A4 (en) * 2015-02-03 2018-10-03 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
CN106366179A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种跨膜硫酸乙酰肝泰蛋白多糖1免疫激动剂多肽及其用途
CN106366180A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种上皮生长因子受体免疫原多肽及其用途
CN106337040A (zh) * 2016-08-28 2017-01-18 苏州普罗达生物科技有限公司 一种内皮细胞受体蛋白酪氨酸激酶a2免疫原多肽及其用途
US20220073630A1 (en) * 2018-12-28 2022-03-10 Hoffmann-La Roche, Inc. A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
CN110093360B (zh) * 2019-04-15 2021-06-15 华南农业大学 一种表达Fc片段的狂犬病病毒G蛋白的融合蛋白及其制备方法
CN112870344B (zh) * 2019-11-29 2022-07-19 北京绿竹生物技术股份有限公司 一种重组水痘带状疱疹病毒疫苗
CN110872358B (zh) * 2019-12-04 2021-12-10 天康制药(苏州)有限公司 HA-Fc融合蛋白及其制备方法和疫苗
CA3211083A1 (en) * 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位
CN119841940B (zh) * 2025-03-19 2025-06-20 中国人民解放军军事科学院军事医学研究院 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
ATE204300T1 (de) * 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
US6391589B1 (en) * 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
EP1093464A2 (en) * 1998-07-06 2001-04-25 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE355374T1 (de) * 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Also Published As

Publication number Publication date
CN101448854A (zh) 2009-06-03
WO2007107797A3 (en) 2007-11-08
WO2007107797A2 (en) 2007-09-27
US20090186025A1 (en) 2009-07-23
EP2007807A2 (en) 2008-12-31
JP2009529906A (ja) 2009-08-27
US20120225067A1 (en) 2012-09-06
CN103396495A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
EP1987484A4 (en) SYSTEMS AND METHOD FOR PLACING ADVERTISING CONTENT
GB0601961D0 (en) Method
GB0603081D0 (en) Method
GB0605735D0 (en) Composition and method for mediating an immune response
GB0709781D0 (en) Composition and method
GB0724967D0 (en) Composition and method
GB0607317D0 (en) Method
GB0606147D0 (en) Method
GB0618001D0 (en) Method
EP2057485A4 (en) ELECTROMAGNETIC DEVICE AND METHOD
EP2026657A4 (en) ANTICANCER COMPOSITION AND METHOD OF USE
PL2132251T3 (pl) Kompozycja i sposób
GB0605323D0 (en) Method
GB0603008D0 (en) Method
GB0604018D0 (en) Method
GB0601699D0 (en) Method
GB0602986D0 (en) Method
GB0615266D0 (en) Composition and method for mediating an immune response
GB0618046D0 (en) Method
GB0625208D0 (en) Composition and method
GB0620930D0 (en) Composition and method for use thereof
GB2453135B (en) Bonding method and component for use therein
GB0611391D0 (en) Method
GB0622580D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)